-+ 0.00%
-+ 0.00%
-+ 0.00%

Black Diamond Therapeutics Q1 FY26 net loss widens to $9.04 million; no revenue

PUBT·05/07/2026 11:23:09
Listen to the news
Black Diamond Therapeutics Q1 FY26 net loss widens to $9.04 million; no revenue
  • Black Diamond Therapeutics posted a net loss of USD 9.04 million for the quarter ended March 31, 2026, swinging from net income of USD 56.54 million a year earlier.
  • Revenue was no revenue versus USD 70 million a year earlier, reflecting the upfront payment received under the Servier agreement in first-quarter 2025.
  • Research and development expense fell to USD 7 million from USD 10.51 million, while general and administrative expense declined to USD 4.26 million from USD 4.96 million.
  • Cash, cash equivalents and investments totaled USD 118.3 million at March 31, 2026; management expects this to fund operations into the second half of 2028.
  • Pipeline update included ongoing Phase 2 development of silevertinib in NSCLC, with updated trial results slated for ASCO May 29–June 2, 2026; first patient was dosed in May 2026 in a randomized Phase 2 trial in newly diagnosed EGFRvIII+ glioblastoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701541-26-000017), on May 07, 2026, and is solely responsible for the information contained therein.